NCT06586294 - A Study of Anti-PD-1 and LAG-3 Bispecific Antibody(AK129) Combined With Chemotherapy With or Without Cadonilimab in the First-line Treatment of Unresectable Locally Advanced or Metastatic G/ GEJ Adenocarcinoma | Biotech Hunter

Enrollment

294

Participants

Timeline

Start Date

September 10, 2024

Primary Completion Date

July 31, 2026

Study Completion Date

July 31, 2026

Conditions

Gastric AdenocarcinomaGastroesophageal Junction Adenocarcinoma

Interventions

DRUG

Drug: AK129 Drug：oxaliplatin Drug：capecitabine

AK129 is administered intravenously according to the frequency every three weeks(Q3W) and different dosage of administration at different stages.Oxaliplatin is administered intravenously according to the frequency and dosage 130 mg/m2 on day 1 Q3W.Capecitabine is administered intravenously according to the frequency and dosage 1000 mg/m2 oral twice daily on day 1 to 14 Q3W.

DRUG

Drug: AK129 Drug：cadonilimab Drug：oxaliplatin Drug：capecitabine

AK129 is administered intravenously according to the frequency Q3W and different dosage of administration at different stages. Cadonilimab is administered intravenously according to the frequency and dosage 10mg/kg Q3W.Oxaliplatin is administered intravenously according to the frequency and dosage 130 mg/m2 on day 1 Q3W.Capecitabine is administered intravenously according to the frequency and dosage 1000 mg/m2 oral twice daily on day 1 to 14 Q3W.

Trial Locations (1)

310005

Zhejiang Cancer Hospital, Hanzhou